In contrast to both meta-analyses, we observed a reduction in HDL cholesterol, similar to another study in which 30 obese subjects received subcutaneous semaglutide once weekly at a dose of 1.0 mg or placebo (42)
Coverage also depends on whether your employer group included weight-loss drugs in the benefit design
Vitamins and hormones 84, 120, doi: 10.1016/B978-0-12-381517-0.00001-1 (2010)
Wegovy is a once-weekly, injectable, prescription weight loss drug
"GLP-1R Agonist Exendin-4 Protects Against Hemorrhagic Transformation Induced by rtPA After Ischemic Stroke via the Wnt/-Catenin Signaling Pathway"
Lees studies are smaller than most rigorous clinical trials, ranging in size from two to 16 study participants, and dont include comparison groups